François Martelet

Chief Executive Officer chez SCANDION ONCOLOGY A/S

Profil

François R.
Martelet currently works at Scandion Oncology A, as Chief Executive Officer from 2023, Novigenix SA, as Independent Director from 2019, and Ennovance Capital LLC, as Senior Advisor.
Dr. Martelet also formerly worked at AVAX Technologies, Inc., as President & Chief Executive Officer from 2007 to 2009, Topotarget A, as Chief Executive Officer & Head-Investor Relations from 2010 to 2012, Vivesto AB, as Chief Executive Officer from 2020 to 2022, NetScientific Plc, as Chief Executive Officer & Executive Director from 2015 to 2019, Vortex BioSciences, Inc., as Chairman, Glycotest, Inc., as Chairman, ProAxsis Ltd., as Chairman, Merck & Co., Inc., as Vice President & Global Franchise Head-Oncology from 2005 to 2006, Novartis AG, as Head-Regional Pharma from 2003 to 2005, and Stallergenes SA, as Senior Vice President-International Operations.
Dr. Martelet received his Masters Business Admin degree and doctorate degree from the University of Dijon, undergraduate degree from Université de Paris 5 René Descartes, and graduate degree from Burgundy School of Business.

Postes actifs de François Martelet

Sociétés	Poste	Début
SCANDION ONCOLOGY A/S	Chief Executive Officer	02/01/2023
Ennovance Capital LLC	Corporate Officer/Principal	27/01/2010
Novigenix SA	Director/Board Member	18/06/2019

Anciens postes connus de François Martelet

Sociétés	Poste	Fin
VIVESTO AB	Chief Executive Officer	21/07/2022
NETSCIENTIFIC PLC	Chief Executive Officer	30/04/2019
TOPOTARGET A/S	Chief Executive Officer	30/08/2012
AVAX TECHNOLOGIES, INC.	Chief Executive Officer	01/01/2009
MERCK & CO., INC.	Corporate Officer/Principal	01/12/2006

Formation de François Martelet

University of Dijon	Doctorate Degree
Burgundy School of Business	Graduate Degree